

Making it through the crisis together.

Now more than ever, it's crucial for people to feel that we are stronger together. The European Union and its member states are collectively mobilising over €3 trillion to help save lives, jobs, and businesses, by supporting the thousands of people working together to make a difference.

#EuropeansAgainstCovid19


It's not in division that we move forward, it's in togetherness: with the researchers, medical staff, scientists, teachers, friends, and neighbours behind the scenes.

Discover European stories of solidarity and hope that encourage all of us to stand strong.

[Testimonials](#)

[Get involved](#)

EN - english



“Solnatide is the first approved treatment for COVID-19 induced lung dysfunctions”

Bernhard

Enables access to new treatments, thanks to EU research funding

📍 **Austria, Vienna**

In most cases, COVID-19 is associated with mild respiratory symptoms. However, in ~15% of the patients, hospitalisation is required, and about 5% of patients develop severe lung injury that can result in acute respiratory distress syndrome (ARDS). In April, solnatide officially became the first treatment for ARDS to be approved for use in Austria and Italy. "We are very happy to be able to supply our Solnatide development drug to the Department of Clinical Pharmacology of the Medical University Vienna. Solnatide is the only therapeutic compound with proof-of-concept results in two clinical studies on patients with severe lung dysfunctions," Bernhard, CEO of APETICO, enthuses. His biotechnology company coordinates an EU-funded project to research coronavirus and develop new medicines. Overall, the European Union provides funding of over EUR 47.5 million for 17 different projects in this area.